Cargando…

Effects of fotemustine or dacarbasine on a melanoma cell line pretreated with therapeutic proton irradiation

BACKGROUND: Considering that HTB140 melanoma cells have shown a poor response to either protons or alkylating agents, the effects of a combined use of these agents have been analysed. METHODS: Cells were irradiated in the middle of the therapeutic 62 MeV proton spread out Bragg peak (SOBP). Irradiat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ristić-Fira, Aleksandra M, Korićanac, Lela B, Žakula, Jelena J, Valastro, Lucia M, Iannolo, Gioacchin, Privitera, Giuseppe, Cuttone, Giacomo, Petrović, Ivan M
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2672057/ https://www.ncbi.nlm.nih.gov/pubmed/19358719 http://dx.doi.org/10.1186/1756-9966-28-50

Ejemplares similares

Carbon ions of different linear energy transfer (LET) values induce apoptosis & G2 cell cycle arrest in radio-resistant melanoma cells
por: Jelena, Žakula, et al.
Publicado: (2016)

Radiosensitivity of human ovarian carcinoma and melanoma cells to γ-rays and protons
por: Keta, Otilija, et al.
Publicado: (2014)

A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
por: Addeo, Raffaele, et al.
Publicado: (2010)

Erratum to: A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
por: Addeo, Raffaele, et al.
Publicado: (2010)

High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial
por: Marinelli, Alfredo, et al.
Publicado: (2018)

Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme
por: Fazeny-Dörner, B, et al.
Publicado: (2003)

Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas
por: Vaccaro, V., et al.
Publicado: (2014)

Regulation of Inflammatory and Proliferative Pathways by Fotemustine and Dexamethasone in Endometriosis
por: Genovese, Tiziana, et al.
Publicado: (2021)

Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.
por: Lee, S. M., et al.
Publicado: (1993)

Proton-irradiated breast cells: molecular points of view
por: Bravatà, Valentina, et al.
Publicado: (2019)

Detailed Analysis of Apoptosis and Delayed Luminescence of Human Leukemia Jurkat T Cells after Proton Irradiation and Treatments with Oxidant Agents and Flavonoids
por: Baran, Irina, et al.
Publicado: (2012)

Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma
por: Santoni, Matteo, et al.
Publicado: (2013)

Fotemustine: A Third-Generation Nitrosourea for the Treatment of Recurrent Malignant Gliomas
por: Beauchesne, Patrick
Publicado: (2012)

Treatment of disseminated ocular melanoma with sequential fotemustine, interferon α, and interleukin 2
por: Becker, J C, et al.
Publicado: (2002)

Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas
por: Corazzelli, Gaetano, et al.
Publicado: (2011)

An Overview of Fotemustine in High-Grade Gliomas: From Single Agent to Association with Bevacizumab
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

The Combination of Carmustine Wafers and Fotemustine in Recurrent Glioblastoma Patients: A Monoinstitutional Experience
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

Retrospective Analysis of Bevacizumab in Combination with Fotemustine in Chinese Patients with Recurrent Glioblastoma Multiforme
por: Liu, Zhiguang, et al.
Publicado: (2015)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

MiR34 inhibition induces human heart progenitor proliferation
por: Iannolo, Gioacchin, et al.
Publicado: (2018)

Viral miRNAs as Active Players and Participants in Tumorigenesis
por: Gallo, Alessia, et al.
Publicado: (2020)

Therapeutic Properties of Mesenchymal Stromal/Stem Cells: The Need of Cell Priming for Cell-Free Therapies in Regenerative Medicine
por: Miceli, Vitale, et al.
Publicado: (2021)

HCV Interplay With Mir34a: Implications in Hepatocellular Carcinoma
por: Badami, Ester, et al.
Publicado: (2022)

Formation and loss of O6-methyldeoxyguanosine in human leucocyte DNA following sequential DTIC and fotemustine chemotherapy.
por: Lee, S. M., et al.
Publicado: (1994)

Immune correlates of metastatic melanoma patients treated with ipilimumab in combination with fotemustine in the phase II NIBIT-M1 study
por: Maccalli, Cristina, et al.
Publicado: (2013)

Zika Virus: A New Therapeutic Candidate for Glioblastoma Treatment
por: Francipane, Maria Giovanna, et al.
Publicado: (2021)

Role of Mesenchymal Stem/Stromal Cells in Modulating Ischemia/Reperfusion Injury: Current State of the Art and Future Perspectives
por: Miceli, Vitale, et al.
Publicado: (2023)

Different priming strategies improve distinct therapeutic capabilities of mesenchymal stromal/stem cells: Potential implications for their clinical use
por: Miceli, Vitale, et al.
Publicado: (2023)

Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation
por: Fabi, Alessandra, et al.
Publicado: (2009)

Upfront Bevacizumab and Temozolomide or Fotemustine before Radiotherapy for Patients with Glioblastoma and Severe Neurological Impairment at Diagnosis
por: Bihan, Celina, et al.
Publicado: (2012)

B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells
por: Roos, Wynand P., et al.
Publicado: (2014)

Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study
por: Addeo, Raffaele, et al.
Publicado: (2019)

Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology)
por: Soffietti, Riccardo, et al.
Publicado: (2013)

Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells.
por: Lee, S. M., et al.
Publicado: (1993)

Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53
por: Naumann, S C, et al.
Publicado: (2009)

Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer.
por: Pujol, J. L., et al.
Publicado: (1994)

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
por: Daponte, Antonio, et al.
Publicado: (2013)

Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine‐based high‐dose chemotherapy regimen
por: Musso, Maurizio, et al.
Publicado: (2015)

Identification and functional interpretation of miRNAs affected by rare CNVs in CAKUT
por: Mitrovic, Kristina, et al.
Publicado: (2022)

Human Amnion-Derived Mesenchymal Stromal Cells: A New Potential Treatment for Carbapenem-Resistant Enterobacterales in Decompensated Cirrhosis
por: Pampalone, Mariangela, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v1cl128ie2mumldgsre0t8jghu